Drug Delivery: Inhalation Devices

Markets covered by this analysis include the US, Japan, and the five major EU markets (France, Germany, Italy, Spain, and the UK). The combined prevalence of asthma and COPD in the countries covered by this report is 109.3 million. The combined market for inhalation drug delivery devices totaled nearly $11.7bn in 2016, and is expected to climb at a rate of 1.2% over the forecast period. Generic erosion will be a key factor in limiting growth in the overall market; however, increasing disease prevalence and the introduction of novel products such as triple combination therapies will offset declines. The US accounts for nearly two-thirds of the overall inhalation drug delivery devices market, and is expected to experience the most growth over the forecast period as its population increases and ages.